metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Adhesión al tratamiento en la enfermedad inflamatoria intestinal: estrategias p...
Información de la revista
Vol. 32. Núm. S2.
Psicología y enfermedad inflamatoria intestinal
Páginas 31-36 (octubre 2009)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 32. Núm. S2.
Psicología y enfermedad inflamatoria intestinal
Páginas 31-36 (octubre 2009)
Psicología y enfermedad inflamatoria intestinal
Acceso a texto completo
Adhesión al tratamiento en la enfermedad inflamatoria intestinal: estrategias para mejorarla
Treatment adherence in inflammatory bowel disease. Strategies for improvement
Visitas
3014
Fernando Bermejo San Joséa,
Autor para correspondencia
fbermejos@medynet.com

Autor para correspondencia.
, Antonio López San Románb, Alicia Algaba Garcíaa
a Servicio de Aparato Digestivo, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España
b Servicio de Gastroenterología, Hospital Universitario Ramón y Cajal, Madrid, España
Este artículo ha recibido
Información del artículo
Resumen

La enfermedad inflamatoria intestinal constituye una entidad clínica en la que hay un riesgo elevado de baja adhesión al tratamiento, debido a que se trata de una enfermedad crónica que afecta con frecuencia a pacientes jóvenes, y que precisa terapias prolongadas en el tiempo y con períodos de inactividad clínica. Diversos factores influyen en la adhesión: las características del paciente y de su enfermedad, la complejidad de su tratamiento y la relación médico-paciente. Debemos intentar detectar la falta de adhesión y tratarla, dada su importancia en los resultados del tratamiento. Para ello podemos realizar un control sistemático en la consulta o centrar la vigilancia en los pacientes no respondedores o en aquellos con factores de riesgo para falta de adhesión. Una buena relación médico-paciente y acciones específicas, como la optimización de la información que se proporciona al paciente acerca de su enfermedad y la elasticidad en la posología respetando la opinión del paciente, pueden ayudar a lograr una buena adhesión al tratamiento.

Palabras clave:
Enfermedad inflamatoria intestinal
Adhesión
Cumplimiento
Tratamiento
Abstract

Since inflammatory bowel disease (IBD) is a chronic condition that frequently affects young patients, requires prolonged therapy and is characterized by periods of clinical remission, there is a risk of low treatment adherence. Adherence is influenced by several factors: disease and patient characteristics, treatment complexity and the physicianpatient relationship. Given the importance of adherence in treatment results, lack of adherence should be detected and treated. To do this, systematic surveillance can be performed in consultations or can be centered on non-responders or patients with risk factors for lack of adherence. Elements that help to achieve good treatment adherence are a good physician-patient relationship and specific actions, such as optimizing the information provided to patients on their disease and dosage adjustments taking the patient's opinion into consideration.

Keywords:
Inflammatory bowel disease
Adherence
Compliance
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.J. Sewitch, M. Abrahamowicz, A. Barkun, A. Bitton, G.E. Wild, A. Cohen, et al.
Patient nonadherence to medication in inflammatory bowel disease.
Am J Gastroenterol, 98 (2003), pp. 1535-1544
[2.]
S. Kane, D. Huo, J. Aikens, S. Hanauer.
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
Am J Medicine, 114 (2003), pp. 39-43
[3.]
A. Robinson.
Review article: improving adherence to medication in patients with inflammatory bowel disease.
Aliment Pharmacol Ther, 27 (2008), pp. 9-14
[4.]
N.J. Hall, G.P. Rubin, A.P. Hungin, A. Dougall.
Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study.
BMC Gastroenterol, 7 (2007), pp. 20
[5.]
K. Schroeder, T. Fahey, S. Ebrahim.
How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials.
Arch Intern Med, 164 (2004), pp. 722-732
[6.]
R.C. Pasternak.
Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults.
Cardiol Clin, 21 (2003), pp. 393-398
[7.]
M.R. DiMatteo.
Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research.
Med Care, 42 (2004), pp. 200-209
[8.]
I. Sánchez-Arcilla, J.M. Vílchez, M. García de la Torre, X. Fernández, A. Noguerado.
Infección tuberculosa latente en población indigente. Comparación de dos pautas terapéuticas.
Med Clin (Barc), 122 (2004), pp. 57-59
[9.]
R.M. Jasmer, P. Nahid, P.C. Hopewell.
Latent tuberculosis infection.
New England J Med, 347 (2002), pp. 1860-1866
[10.]
R.L. Levy, A.D. Feld.
Increasing patient adherence to gastroenterology treatment and prevention regimens.
Am J Gastroenterol, 94 (1999), pp. 1733-1742
[11.]
S.V. Kane, R.D. Cohen, J.E. Aikens, S.B. Hanauer.
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
Am J Gastroenterol, 96 (2001), pp. 2929-2933
[12.]
S.V. Kane.
Systematic review: adherente issues in the treatment of ulcerative colitis.
Aliment Pharmacol Ther, 23 (2006), pp. 577-585
[13.]
G. Rubin, A.P. Hungin, D. Chinn, A.D. Dwarakanath, L. Green, J. Bates.
Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey.
Aliment Pharmacol Ther, 16 (2002), pp. 1889-1893
[14.]
López-San Román, F. Bermejo, E. Carrera, M. Pérez-Abad, D. Boixeda.
Adherence to treatment in inflammatory bowel disease.
Rev Esp Enferm Dig, 97 (2005), pp. 249-257
[15.]
I. Bernal, E. Domènech, E. García-Planella, L. Marín, M. Mañosa, M. Navarro, et al.
Medication-taking behaviour in a cohort of patients with inflammatory bowel disease.
Dig Dis Sci, 51 (2006), pp. 2165-2169
[16.]
M.J. Shale, S.A. Riley.
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
Aliment Pharmacol Ther, 18 (2003), pp. 191-198
[17.]
R. D’Incà, P. Bertomoro, K. Mazzocco, M.G. Vettorato, R. Rumiati, G.C. Sturniolo.
Risk factors for non-adherence to medication in inflammatory bowel disease patients.
Aliment Pharmacol Ther, 27 (2008), pp. 166-172
[18.]
A.B. Hawthorne, G. Rubin, S. Ghosh.
Review article: medication non-adherence in ulcerative colitis–strategies to improve adherence with mesalazine and other maintenance therapies.
Aliment Pharmacol Ther, 27 (2008), pp. 1157-1166
[19.]
A. López-Sanromán, F. Bermejo.
Review article: how to control and improve adherence to therapy in inflammatory bowel disease.
Aliment Pharmacol Ther, 24 (2006), pp. 45-49
[20.]
F. Bermejo, A. López-Sanromán, A. Algaba, J.A. Carneros, M.P. Valer, S. Sánchez, et al.
What factors influence adhesion to therapy in inflammatory bowel disease?.
J Crohn's Colitis, 3 (2009), pp. S49
[21.]
A. López-Sanromán, F. Bermejo, E. Carrera, A. García-Plaza.
Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis.
Aliment Pharmacol Ther, 20 (2004), pp. 161-166
[22.]
B. Bokemeyer, A. Teml, C. Roggel, P. Hartmann, C. Fischer, E. Schaeffeler, et al.
Adherence to thiopurine treatment in out-patients with Crohn's disease.
Aliment Pharmacol Ther, 26 (2007), pp. 217-225
[23.]
B.M. Waters, L. Jensen, R. Fedorak.
Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial.
Can J Gastroenterol, 19 (2005), pp. 235-244
[24.]
F.S. Velayos, J.P. Terdiman, J.M. Walsh.
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies.
Am J Gastroenterol, 100 (2005), pp. 1345-1353
[25.]
T.P. Van Staa, T. Card, R.F. Logan, H.G. Leufkens.
Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
Gut, 54 (2005), pp. 1573-1578
[26.]
A. Robinson, D.G. Thompson, D. Wilkin, C. Roberts, Northwest Gastrointestinal Research Group.
Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.
[27.]
A.P. Kennedy, E. Nelson, D. Reeves, G. Richardson, C. Roberts, A. Robinson, et al.
A randomised controlled trial to assess the effectiveness and cost pf a patient orientated self management approach to chronic inflammatory bowel disease.
Gut, 53 (2004), pp. 1639-1645
[28.]
A.J. Claxton, J. Cramer, C. Pierce.
A systematic review of the associations between dose regimens and medication compliance.
Clin Ther, 23 (2001), pp. 1296-1310
[29.]
M.A. Kamm, G.R. Lichtenstein, W.J. Sandborn, S. Schreiber, K. Lees, K. Barrett, et al.
Randomised trial of once– or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
[30.]
W. Kruis, G. Kiudelis, I. Rácz, I.A. Gorelov, J. Pokrotnieks, M. Horynski, International Salofalk OD Study Group, et al.
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
[31.]
B. Bokemeyer, A. Dignass, T. Stijnen, H. Veerman.
Higher remission rates in patients with once-daily dosing compared to twice-daily dosing. An analysis of compliance in the once daily vs. twice daily podium trial with mesalazine (Pentasa®) sachets.
J Crohn's Colitis, 3 (2009), pp. S78
Copyright © 2009. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos